These data highlight the importance of understanding the contribution of IL-13 and its integrating and signaling genes in NASH-HCC pathogenesis, and if validated, may contribute to a tailored, personalized approach to cost effective surveillance and detection, possibly targeting NASH-HCC patients. This evidence concerns the gene IL13 and metabolic dysfunction-associated steatohepatitis.